Indolent Systemic Mastocytosis Clinical Trials

18 clinical trials for Indolent Systemic Mastocytosis across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) — RECRUITING
• (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis — RECRUITING · PHASE2
• A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany — RECRUITING
• A PHASE 2 MULTICENTER STUDY OF TL-895 IN SUBJECTS WITH MYELOFIBROSIS, INDOLENT SYSTEMIC MASTOCYTOSIS, MONOCLONAL MAST CELL ACTIVATION SYNDROME, OR NONMONOCLONAL MAST CELL ACTIVATION SYNDROME — RECRUITING · PHASE2
• A 3-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVAPRITINIB (BLU-285), A SELECTIVE KIT MUTATION-TARGETED TYROSINE KINASE INHIBITOR, IN INDOLENT AND SMOLDERING SYSTEMIC MASTOCYTOSIS WITH SYMPTOMS INADEQUATELY CONTROLLED WITH STANDARD THERAPY — RECRUITING · PHASE2
• A Phase 2 Multicenter Study of TL-895 in Subjects with Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Activation Syndrome — TERMINATED · PHASE2
• A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU 285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy — TERMINATED · PHASE2
• (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis — ACTIVE_NOT_RECRUITING · PHASE2
• Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis — COMPLETED · PHASE2
• Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis — OTHER · PHASE2
• Angioedema Biomarker Research Study — OTHER
• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment — OTHER · PHASE3
• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis — COMPLETED · PHASE3
• Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language — COMPLETED
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 — COMPLETED · PHASE1
• Treatment of Indolent Systemic Mastocytosis With PA101 — COMPLETED · PHASE2
• Midostaurin in Indolent Systemic Mastocytosis — OTHER · PHASE2
• A 24-WEEK WITH POSSIBLE EXTENSION, PROSPECTIVE, MULTICENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, 2-PARALLEL GROUP WITH A RANDOMIZATION 1:1, PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF MASITINIB AT 6 MG/KG/DAY TO PLACEBO IN TREATMENT OF PATIENTS WITH SMOULDERING SYSTEMIC, INDOLENT SYSTEMIC OR CUTANEOUS MASTOCYTOSIS WITH HANDICAP — NOT_YET_RECRUITING · PHASE3

Refine this search